---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-024336"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:47:47.377633+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics enters Roche DAC collaboration; $20M upfront, >$1B milestones

## Summary
- $20M upfront from Roche for two DAC programs targeting undisclosed oncology targets.
- Eligible for over $1B in discovery, regulatory, and commercial milestones plus tiered royalties (mid-single to low-double digit).
- Roche responsible for all development, regulatory, manufacturing, and commercialization costs.
- Option for a third target with additional payment, milestones, and royalties.
- Leverages C4T's TORPEDO platform for degrader payloads and Roche's ADC expertise.

## SEC filing metadata
- accession: 0001628280-26-024336
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828026024336/0001628280-26-024336-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828026024336/cccc-20260409.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-024336
- JSON: https://secwatch.observer/filing/0001628280-26-024336.json
- Plain text: https://secwatch.observer/filing/0001628280-26-024336.txt

## Source-grounded claims
- claim_id: b856d8e0c3f12899f01e27b31eae6dc4e4d74dc7
  claim: C4 Therapeutics, Inc. entered into "License Agreement" with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (together, "Roche") valued at $20.0 million upfront, over $1.0 billion in aggregate milestone payments (effective 2026-04-08).
  evidence_excerpt: On April 8, 2026 , C4 Therapeutics, Inc. (“ C4T ”) entered into a Research Collaboration and License Agreement ( the “ License Agreement ”) with F. Hoffmann-La Roche Ltd. (“ Roche Basel ”) and Hoffmann-La Roche Inc. (“ Roche US ”, and together with Roche Basel, “ Roche ”) to collaborate on the discovery, development and commercialization of degrader-antibody conjugates (" DACs ")
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828026024336/0001628280-26-024336-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.